{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:37:10Z","timestamp":1784547430464,"version":"3.55.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-cardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jjcc.2025.09.010","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T06:56:30Z","timestamp":1758178590000},"page":"550-556","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cardiovascular-related hospital visits amongst oncology patients receiving immune checkpoint inhibitors: a population-based cohort study"],"prefix":"10.1016","volume":"87","author":[{"given":"Wei Fang","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Habbous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Husam","family":"Abdel-Qadir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun G.","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelvin K.W.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jjcc.2025.09.010_bb0005","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","author":"Robert","year":"2020","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.jjcc.2025.09.010_bb0010","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1016\/j.jjcc.2025.09.010_bb0015","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jjcc.2025.09.010_bb0020","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/s12885-020-06798-1","article-title":"Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada","volume":"20","author":"Dai","year":"2020","journal-title":"BMC Cancer"},{"issue":"14","key":"10.1016\/j.jjcc.2025.09.010_bb0025","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"issue":"6477","key":"10.1016\/j.jjcc.2025.09.010_bb0030","doi-asserted-by":"crossref","DOI":"10.1126\/science.aax0182","article-title":"Neoadjuvant checkpoint blockade for cancer immunotherapy","volume":"367","author":"Topalian","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.jjcc.2025.09.010_bb0035","doi-asserted-by":"crossref","unstructured":"O'Donnell JS, Hoefsmit EP, Smyth MJ, Blank CU, Teng MWL. The promise of neoadjuvant immunotherapy and surgery for cancer treatment. Clin Cancer Res [Internet] 2019 Oct 1 [cited 2022 Oct 3];25(19):5743\u201351. Available fromhttps:\/\/aacrjournals.org\/clincancerres\/article\/25\/19\/5743\/124633\/The-Promise-of-Neoadjuvant-Immunotherapy-and","DOI":"10.1158\/1078-0432.CCR-18-2641"},{"issue":"7","key":"10.1016\/j.jjcc.2025.09.010_bb0040","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/d41573-022-00030-4","article-title":"Challenges and opportunities in the PD1\/PDL1 inhibitor clinical trial landscape","volume":"21","author":"Upadhaya","year":"2022","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"10.1016\/j.jjcc.2025.09.010_bb0045","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3390\/cancers12030738","article-title":"Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence","volume":"12","author":"Vaddepally","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.jjcc.2025.09.010_bb0050","doi-asserted-by":"crossref","unstructured":"Twomey JD, Zhang B. Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics. AAPS J [Internet]. 2021 Mar 1 [cited 2023 Mar 5];23(2):1\u201311. Available fromhttps:\/\/link.springer.com\/article\/10.1208\/s12248-021-00574-0","DOI":"10.1208\/s12248-021-00574-0"},{"key":"10.1016\/j.jjcc.2025.09.010_bb0055","unstructured":"Phillips AL, Reeves DJ. Nivolumab\/Relatlimab: a novel addition to immune checkpoint inhibitor therapy in unresectable or metastatic melanoma. https:\/\/doi.org\/101177\/10600280221131396 [Internet]. 2022 Oct 21 [cited 2023 Mar 5]; Available fromhttps:\/\/journals.sagepub.com\/doi\/10.1177\/10600280221131396?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed"},{"issue":"1","key":"10.1016\/j.jjcc.2025.09.010_bb0060","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1016\/S2352-3026(18)30175-3","article-title":"Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study","volume":"6","author":"Delanoy","year":"2019","journal-title":"Lancet Haematol"},{"issue":"11","key":"10.1016\/j.jjcc.2025.09.010_bb0065","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.2174\/0929867324666170407125017","article-title":"Immune checkpoint inhibitors and cardiac toxicity: an emerging issue","volume":"25","author":"V","year":"2018","journal-title":"Curr Med Chem"},{"issue":"10124","key":"10.1016\/j.jjcc.2025.09.010_bb0070","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.jjcc.2025.09.010_bb0075","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med [Internet]"},{"key":"10.1016\/j.jjcc.2025.09.010_bb0080","unstructured":"Makunts T, Saunders IM, Cohen I V., Li M, Moumedjian T, Issa MA, et al. Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data. Sci Rep 2021 11:1 [Internet]. 2021 Aug 30 [cited 2023 Mar 5];11(1):1\u201315. Available fromhttps:\/\/www.nature.com\/articles\/s41598-021-96467-5"},{"key":"10.1016\/j.jjcc.2025.09.010_bb0085","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ejca.2021.01.043","article-title":"Cardiotoxicity of immune checkpoint inhibitors: a systematic review and meta-analysis of randomised clinical trials","volume":"148","author":"Agostinetto","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jjcc.2025.09.010_bb0090","doi-asserted-by":"crossref","unstructured":"Rahouma M, Karim NA, Baudo M, Yahia M, Kamel M, Eldessouki I, et al. Cardiotoxicity with immune system targeting drugs: A meta-analysis of anti-PD\/PD-L1 immunotherapy randomized clinical trials. Immunotherapy [Internet]. 2019 May 15 [cited 2023 Mar 5];11(8):725\u201335. Available fromwww.futuremedicine.com","DOI":"10.2217\/imt-2018-0118"},{"key":"10.1016\/j.jjcc.2025.09.010_bb0095","doi-asserted-by":"crossref","unstructured":"Dolladille C, Akroun J, Morice PM, Dompmartin A, Ezine E, Sassier M, et al. Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis. Eur Heart J [Internet] 2021 Dec 21 [cited 2023 Mar 5];42(48):4964\u201377. Available fromhttps:\/\/academic.oup.com\/eurheartj\/article\/42\/48\/4964\/6371301","DOI":"10.1093\/eurheartj\/ehab618"},{"key":"10.1016\/j.jjcc.2025.09.010_bb0100","unstructured":"Mahmood SS, Fradley MG, Cohen J V., Nohria A, Reynolds KL, Heinzerling LM, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol [Internet]. 2018 Apr 24 [cited 2022 Aug 28];71(16):1755\u201364. Available fromhttps:\/\/pubmed.ncbi.nlm.nih.gov\/29567210\/"},{"issue":"12","key":"10.1016\/j.jjcc.2025.09.010_bb0105","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"issue":"76","key":"10.1016\/j.jjcc.2025.09.010_bb0110","article-title":"Myocarditis following the use of different immune checkpoint inhibitor regimens: a real-world analysis of post-marketing surveillance data","author":"Fan","year":"2019","journal-title":"Int Immunopharmacol"},{"issue":"9","key":"10.1016\/j.jjcc.2025.09.010_bb0115","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s40264-021-01086-8","article-title":"Immune checkpoint inhibitors and cardiotoxicity: an analysis of spontaneous reports in Eudravigilance","volume":"44","author":"Mascolo","year":"2021","journal-title":"Drug Saf"},{"issue":"29","key":"10.1016\/j.jjcc.2025.09.010_bb0120","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1200\/JCO.21.01808","article-title":"Incidence of cardiovascular events in patients treated with immune checkpoint inhibitors","volume":"40","author":"Laenens","year":"2022","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.jjcc.2025.09.010_bb0125","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1093\/eurheartj\/ehaa884","article-title":"The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study","volume":"42","author":"D\u2019Souza","year":"2021","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.jjcc.2025.09.010_bb0130","first-page":"10","article-title":"Newly diagnosed cardiovascular disease in patients treated with immune checkpoint inhibitors: a retrospective analysis of patients at an academic tertiary care center","volume":"7","author":"Waheed","year":"2021","journal-title":"Cardio-Oncol"},{"key":"10.1016\/j.jjcc.2025.09.010_bb0135","doi-asserted-by":"crossref","unstructured":"Furukawa A, Tamura Y, Taniguchi H, Kawamura A, Nagase S, Hayashi A, et al. Prospective screening for myocarditis in cancer patients treated with immune checkpoint inhibitors. J Cardiol [Internet]. 2023 Jan 1 [cited 2025 Apr 18];81(1):63\u20137. Available fromhttps:\/\/pubmed.ncbi.nlm.nih.gov\/35953399\/","DOI":"10.1016\/j.jjcc.2022.07.009"},{"key":"10.1016\/j.jjcc.2025.09.010_bb0140","doi-asserted-by":"crossref","unstructured":"Oikawa M, Ishida T, Takeishi Y. Cancer therapeutics-related cardiovascular dysfunction: basic mechanisms and clinical manifestation. J Cardiol [Internet]. 2023 Mar 1 [cited 2025 Apr 12];81(3):253\u20139. Available fromhttps:\/\/www.journal-of-cardiology.com\/action\/showFullText?pii=S0914508722000946","DOI":"10.1016\/j.jjcc.2022.04.006"},{"key":"10.1016\/j.jjcc.2025.09.010_bb0145","doi-asserted-by":"crossref","unstructured":"Suero-Abreu GA, Zanni M V., Neilan TG. Atherosclerosis with immune checkpoint inhibitor therapy: evidence, diagnosis, and management: JACC: cardioOncology state-of-the-art review. Cardio Oncol [Internet]. 2022 Dec 1 [cited 2023 Mar 5];4(5):598\u2013615. Available fromhttps:\/\/www.jacc.org\/doi\/10.1016\/j.jaccao.2022.11.011","DOI":"10.1016\/j.jaccao.2022.11.011"},{"key":"10.1016\/j.jjcc.2025.09.010_bb0150","series-title":"2016 Census of population. The daily: component of statistics Canada catalogue no. 11-001-X","author":"Statistics Canada","year":"2018"},{"issue":"11","key":"10.1016\/j.jjcc.2025.09.010_bb0155","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"issue":"2","key":"10.1016\/j.jjcc.2025.09.010_bb0160","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1161\/CIRCOUTCOMES.114.001416","article-title":"The cardiovascular health in ambulatory care research team (CANHEART): using big data to measure and improve cardiovascular health and healthcare services","volume":"8","author":"Tu","year":"2015","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jjcc.2025.09.010_bb0165","doi-asserted-by":"crossref","unstructured":"Wang DY, Salem JE, Cohen J V., Chandra S, Menzer C, Ye F, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and Meta-analysis. JAMA Oncol [Internet] 2018 Dec 1 [cited 2022 Aug 28];4(12):1721\u20138. Available fromhttps:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2701721","DOI":"10.1001\/jamaoncol.2018.3923"}],"container-title":["Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508725002400?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508725002400?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T02:43:02Z","timestamp":1780281782000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0914508725002400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0914508725002400"],"URL":"https:\/\/doi.org\/10.1016\/j.jjcc.2025.09.010","relation":{},"ISSN":["0914-5087"],"issn-type":[{"value":"0914-5087","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular-related hospital visits amongst oncology patients receiving immune checkpoint inhibitors: a population-based cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jjcc.2025.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Japanese College of Cardiology. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}